The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia
There are currently no regulatory approved pharmacological treatments for cognitive impairment associated with schizophrenia (CIAS). One possibility is that trial methodology itself is hindering their development. Emerging evidence suggests that patients with schizophrenia may show limited benefit f...
Main Authors: | Jack Cotter, Jennifer H. Barnett, Kiri Granger |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-09-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fpsyt.2019.00648/full |
Similar Items
-
How do participants in clinical trials compare with other patients with schizophrenia?
by: Robert Freudenthal, et al.
Published: (2021-06-01) -
Prescribing habits in the pharmacotherapy of schizophrenia
by: King, Russell Wayne
Published: (2011) -
Mindfulness-Based Social Cognition Training (SocialMind) for People With Psychosis: A Feasibility Trial
by: Roberto Mediavilla, et al.
Published: (2019-05-01) -
Comparing Randomized Controlled Trials and Real-World Studies in Chronic Obstructive Pulmonary Disease Pharmacotherapy
by: Tashkin DP, et al.
Published: (2020-06-01) -
Cognitive impairments in schizophrenia in foreign studies: single function deficits or group of syndromes?
by: Karyakina M.V., et al.
Published: (2021-06-01)